CIM LLC’s Krystal Biotech KRYS Stock Holding History

CIM LLC’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.84M	Buy	15,703 +713	+5%	+$213K	0.75%	35
2026 Q1	$3.87M	Buy	+14,990	New	+$3.99M	0.56%	42

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CIM LLC's KRYS Position: Q2 2026 in Review

CIM LLC increased its Krystal Biotech (KRYS) stake by 4.8% in Q2 2026, buying an estimated $213K and bringing the position to 15,703 shares worth $5.84M. The position accounts for 0.75% of the portfolio, ranked #35.

CIM LLC first reported a position in KRYS in Q1 2026 and has held it in 2 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

CIM LLC held 15,703 shares of Krystal Biotech worth $5.84M as of Q2 2026.
CIM LLC bought 713 Krystal Biotech shares in Q2 2026, an estimated $213K.
Krystal Biotech made up 0.75% of CIM LLC's portfolio in Q2 2026, its #35 holding.
CIM LLC first reported a position in Krystal Biotech in Q1 2026 and has held it in 2 quarters since.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on CIM LLC's 13F filing for Q2 2026, filed 13 Aug 2026.